<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; channel</title>
	<atom:link href="http://www.tapanray.in/tag/channel/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>This New Engagement Model Garners Significant Rewards For Pharma</title>
		<link>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=this-new-engagement-model-garners-significant-rewards-for-pharma</link>
		<comments>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/#comments</comments>
		<pubDate>Mon, 28 Nov 2022 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[cyberspace]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[difference]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10731</guid>
		<description><![CDATA[Last year, on July 26, 2021, I wrote in this blog on gaining a competitive edge with Omnichannel pharma marketing Omnichannel pharma marketing. However, from several recent studies, it appears, it’s still remains in a nascent stage. Most players in the industry haven’t &#8230; <a href="http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Expand Market Share Unleashing Digital Health Potential For All</title>
		<link>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=expand-market-share-unleashing-digital-health-potential-for-all</link>
		<comments>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/#comments</comments>
		<pubDate>Mon, 15 Nov 2021 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adoption]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequity]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Share]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10609</guid>
		<description><![CDATA[“Advancement in digital health is currently restricted mainly to economically and socially privileged populations. Those having access, resources and basic digital skills, are reaping disproportionate benefits from the technology and other associated infrastructure available for this purpose. Unfortunately, underserved population, &#8230; <a href="http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time To Audit Pharma’s Doctor-Engagement And Other Digital Strategies</title>
		<link>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies</link>
		<comments>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/#comments</comments>
		<pubDate>Mon, 25 Jan 2021 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[audit]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[e-visits]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[format]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value-delivery]]></category>
		<category><![CDATA[walk the talk]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10400</guid>
		<description><![CDATA[It’s now over a year since the unprecedented global health crisis commenced. In this grueling saga, a silver lining is also visible. It helped pharma industry gain a fascinating operational experience, while navigating through disruptive business changes. The changes in the &#8230; <a href="http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma ‘Chatbots’: For Better Stakeholder Engagement</title>
		<link>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-chatbots-for-better-stakeholder-engagement</link>
		<comments>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/#comments</comments>
		<pubDate>Mon, 29 Jul 2019 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[answers]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[assistant]]></category>
		<category><![CDATA[automated]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[Chatbots]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[functions]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Privacy]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[questions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[satisfaction]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9647</guid>
		<description><![CDATA[The critical value of meaningful interaction and engagement with individual customers &#8211; responding to their specific needs, is fast drawing attention of many businesses, for sustainable performance excellence. The same is happening in the pharma industry, as well. Creative use &#8230; <a href="http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-chatbots-for-better-stakeholder-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Multichannel Marketing: Two Important Pharma Trends</title>
		<link>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=multichannel-marketing-two-important-pharma-trends</link>
		<comments>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/#comments</comments>
		<pubDate>Mon, 10 Sep 2018 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[dinner]]></category>
		<category><![CDATA[importance]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCM]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[meetings]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[print]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9149</guid>
		<description><![CDATA[On September 6, 2018, Reuters reported the announcement of GlaxoSmithKline (GSK) that it would cut about 650 positions in the United States related to a global restructuring program. This includes 450 Medical (sales) Representatives (MR). Similar announcements on job cuts for MRs &#8230; <a href="http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Multi-channel Engagement: A New Normal In Pharma Marketing</title>
		<link>http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=multi-channel-engagement-a-new-normal-in-pharma-marketing</link>
		<comments>http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/#comments</comments>
		<pubDate>Mon, 26 Dec 2016 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8021</guid>
		<description><![CDATA[The 2015 Report of AffinityMonitor reconfirms that access to important doctors for pharma Medical Representatives (MRs) continues to decline. Now, fewer than half of all doctors are truly accessible to the MRs, down from nearly 80 percent in 2008. In &#8230; <a href="http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
